Z20.6 is a clinical classification used for individuals who have had a known or suspected exposure to the Human Immunodeficiency Virus (HIV) but have not yet received a confirmed diagnosis of infection. This code is frequently utilized in clinical settings for initial risk assessments, baseline testing following a high-risk event, and the initiation of Post-Exposure Prophylaxis (PEP). Common scenarios requiring this code include occupational exposures such as needlestick injuries in healthcare workers, non-occupational exposures such as unprotected sexual contact with a partner of positive or unknown HIV status, sharing of injection drug equipment, or accidental contact with infected blood or body fluids. The primary goal of the clinical encounter is to evaluate the level of risk, provide counseling, and initiate preventative interventions within the critical 72-hour window following exposure.
Distinguish between occupational and non-occupational exposure categories clearly in the clinical narrative.
Example: Patient is a registered nurse who sustained a percutaneous injury via a 22-gauge hollow-bore needle while performing venipuncture on a patient with a known history of HIV and a detectable viral load. Billing focus: Specificity of exposure route and source status. Risk Adjustment: High complexity of medical decision making due to the risk of transmission from a known positive source.
Billing Focus: Documentation of the specific mechanism of exposure and the nature of the potentially infectious material.
Record the time elapsed from the moment of exposure to the initiation of the encounter to justify urgency and PEP efficacy.
Example: Patient presents for evaluation of a non-occupational exposure (unprotected receptive anal intercourse) occurring 4 hours prior to arrival. Source HIV status is unknown. Billing focus: Timing of encounter within the 72-hour window for PEP. Risk Adjustment: Justifies the acute necessity of antiretroviral therapy and intensive monitoring.
Billing Focus: Chronology of events to support the medical necessity of rapid prophylactic intervention.
Explicitly document the HIV status of the source patient if known or if the source is from a high-prevalence population.
Example: Patient was exposed to blood via splash to the conjunctiva during a trauma resuscitation. The source patient was subsequently identified as HIV positive with unknown antiretroviral history. Billing focus: Source patient identifier and known serostatus. Risk Adjustment: Increased risk profile for the exposed patient requiring more frequent follow-up testing.
Billing Focus: Source documentation helps establish the level of risk and determines the duration and intensity of the follow-up period.
Detail the initiation and specific regimen of Post-Exposure Prophylaxis (PEP) including dosage and duration.
Example: Initiated a 28-day course of Emtricitabine 200 mg / Tenofovir disoproxil fumarate 300 mg once daily plus Dolutegravir 50 mg once daily. Patient educated on adherence and potential side effects including renal and hepatic toxicity. Billing focus: Therapeutic drug management and counseling. Risk Adjustment: High-risk management involving prescription drug monitoring and toxicity risk.
Billing Focus: Supports the use of CPT codes for counseling and intensive drug monitoring visits.
Incorporate baseline laboratory testing results and the schedule for serial follow-up testing in the treatment plan.
Example: Baseline HIV 1/2 Ag/Ab, Hepatitis B sAb, Hepatitis C Ab, and Syphilis screen performed today. Repeat HIV testing scheduled for 4 weeks and 3 months post-exposure. Renal function and LFTs to be checked at 2 weeks. Billing focus: Laboratory order specificity and follow-up plan. Risk Adjustment: Demonstrates a comprehensive management plan for a potentially life-altering condition.
Billing Focus: Justifies the medical necessity for repeated diagnostic procedures and follow-up evaluation and management visits.
Applies to straightforward exposure cases where the source is low risk and counseling is primary.
Appropriate for routine follow-up where the patient is stable and risks are clearly defined.
Used when PEP leads to complications or if there are multiple co-occurring exposures (e.g., HIV and Hep C).
Standard baseline and follow-up test for individuals with suspected exposure.
Used in high-risk exposures to detect early infection before antibody seroconversion.
Supports the extensive education required for PEP and future prevention.
Used if injectable antiretrovirals are part of the prophylaxis or for co-occurring exposures like Tetanus or Hepatitis B.
Required to monitor for organ toxicity while the patient is on PEP.
Specific HCPCS code often used for Medicare/Medicaid HIV screening encounters.
The risk of transmission and the narrow window for PEP initiation justify a moderate complexity ED visit.